ReviewTrends in molecular medicine2010
Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells.
Review in Trends in molecular medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 102 citations in OpenAlex.
- HES1 inhibition overcomes CDK4/6 inhibitor resistance by targeting cancer stemness in lung adenocarcinoma.Journal of experimental & clinical cancer research : CR · 2026Article
- Aerobic exercise significantly altersJournal of Alzheimer's disease : JAD · 2026Article
- HES1 revitalizes the functionality of aged adipose-derived stem cells by inhibiting the transcription of STAT1.Stem cell research & therapy · 2024Article
- A cell cycle centric view of tumour dormancy.British journal of cancer · 2023Review
- The HDAC inhibitor domatinostat induces type I interferon α in Merkel cell carcinoma by HES1 repression.Journal of cancer research and clinical oncology · 2023Article
- Therapeutic Effectiveness of Anticancer Agents Targeting Different Signaling Molecules Involved in Asymmetric Division of Cancer Stem Cell.Stem cell reviews and reports · 2023Review
- HES1-mediated down-regulation of miR-138 sustains NOTCH1 activation and promotes proliferation and invasion in renal cell carcinoma.Journal of experimental & clinical cancer research : CR · 2023Article
- Article
- Calcitonin Gene-Related Peptide Attenuates Hyperoxia-Induced Oxidative Damage in Alveolar Epithelial Type II Cells Through Regulating Viability and Transdifferentiation.Inflammation · 2022Article
- Constructing a new prognostic signature of gastric cancer based on multiple data sets.Bioengineered · 2021Article
- Differential phase register of Hes1 oscillations with mitoses underlies cell-cycle heterogeneity in ERProceedings of the National Academy of Sciences of the United States of America · 2021Article
- Is There a Histone Code for Cellular Quiescence?Frontiers in cell and developmental biology · 2021Review
- Unraveling the Big Sleep: Molecular Aspects of Stem Cell Dormancy and Hibernation.Frontiers in physiology · 2021Review
- Article
- GANT61 and Valproic Acid Synergistically Inhibited Multiple Myeloma Cell Proliferation via Hedgehog Signaling Pathway.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- CPF impedes cell cycle re-entry of quiescent lung cancer cells through transcriptional suppression of FACT and c-MYC.Journal of cellular and molecular medicine · 2020Article
- PTBP3 Induced Inhibition of Differentiation of Gastric Cancer Cells Through Alternative Splicing of Id1.Frontiers in oncology · 2020Article
- The promising role of PAX1 (aliases: HUP48, OFC2) gene methylation in cancer screening.Molecular genetics & genomic medicine · 2019Review
- Targeting tumor cell plasticity by combined inhibition of NOTCH and MAPK signaling in colon cancer.The Journal of experimental medicine · 2018Article
- Noise in the Vertebrate Segmentation Clock Is Boosted by Time Delays but Tamed by Notch Signaling.Cell reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Quiescent and tumor cells share the ability to evade irreversible cell fates. Recent studies have shown that the transcriptional regulator Hairy and Enhancer of Split 1 (HES1) protects quiescent fibroblasts from differentiation or senescence. HES1 is highly expressed in rhabdomyosarcomas, and the inhibition of HES1 restores differentiation in these cells. Pathways that lead to elevated HES1 levels, such as the Notch and Hedgehog pathways, are frequently upregulated in tumors. Compounds that inhibit these pathways induce differentiation and apoptosis in cancer cells and several are in clinical trials. HES1 might repress gene expression in part by recruiting histone deacetylases (HDACs). HDACs inhibit differentiation, whereas histone deacetylase inhibitors (HDACis) induce differentiation or apoptosis in tumors and are also showing promise as therapeutics. Small molecules that directly target HES1 itself were recently identified. Here, we discuss the importance of HES1 function in quiescent and tumor cells. Elucidating the pathways that control quiescence could provide valuable information not only for treating cancer but also other diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.